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Problem Definition

Intervention

Lessons Learned

Adrenal insufficiency after transsphenoidal
resection of pituitary adenoma (PA) can be
seen in 1-12% of cases. In PA, the use of
postoperative cortisol measurement and
supplementation remains controversial. It is
unclear whether postoperative cortisol
supplementation has a measurable effect on
improving outcomes in patients with
pituitary adenoma undergoing endoscopic
transsphenoidal surgery (ETS). The
objective of the study was to evaluate a
postoperative steroid treatment protocol in
patients with PA undergoing ETS.

A retrospective cohort study was
performed for patients undergoing ETS
from 2005 to 2020 for PA at a single
tertiary academic center. Patients were
divided into two groups: those managed
by a routine postoperative glucocorticoid
supplementation protocol (standard
protocol) and those that received
supplementation based on postoperative
cortisol laboratory assessment (sparing
protocol). Management was otherwise the
same between groups. Both univariate
and multivariate analysis was performed.

In patients who underwent endoscopic
transsphenoidal surgery for pituitary
adenoma, there were no differences in
outcomes between those on the standard
postoperative steroids protocol and those
on the postoperative steroid sparing
protocol. This suggests that the routine
administration of glucocorticoids may not
be necessary following surgery for pituitary
adenoma.

Aims For Improvement
S: develop a steroid sparing protocol for
PA patients undergoing ETS.
M: measure steroid administration and
levels, as well as outcomes.
A: achievable because involves small
protocol modification.
R: relevant because this can spare
unnecessary medication.
T: test over the period of multiple years.

Measurements/ Results
Among 535 patients, 21% (n=111)
received postoperative steroids, while the
remainder (n=424) did not. There were
no differences in mean length of stay (3
days vs. 3 days, p=0.72), sinonasal
complaints (27% vs. 19%, p=0.12), 30-day
readmission (5% vs. 5%, p=0.44), and
perioperative complications (5% vs. 5%,
p=0.79) between both the groups. A
multivariate model also supported that
both groups were comparable in
predicting length of stay, 30-day
readmission, and complications.
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